Hofseth Biocare ASA (HOFBC.OL)
* Q3 OPERATING REVENUE NOK 27.9 MILLION VERSUS NOK 3.6 MILLION YEAR AGO
* REG-HOFSETH BIOCARE ASA: HBC ENTERS INTO A NEW NOK 35M FINANCING AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)
OSLO, Oct 10 Norwegian biotech firm Hofseth Biocare expects to report stronger results ahead as it enters a new commercial phase, its chief executive officer told Reuters, after reporting higher preliminary figures for the third quarter on Tuesday.
* BASED ON PRELIMINARY FIGURES FOR Q3 2017, HOFSETH EXPECTS TO REPORT GROUP REVENUES OF ABOUT NOK 28M FOR QUARTER
* TOR ERIK S. ANDERSEN HAS CHOSEN TO LEAVE HIS POSITION AS CEO OF HBC